Efficacy of rituximab in primary immune thrombocytopenia: An analysis of adult pretreated patients from everyday hematological practice

International Journal of Hematology

Volumn 96, Issue 5, 2012, Pages 594-599

  Červinek, Libor ^a   Černá, Olga ^b   Čaniga, Miroslav ^c   Konířová, Eva ^d   Hluší, Antonín ^e   Šimkovič, Martin ^b   Pospíšil, Zdeněk ^f   Čermák, Jarosla ^c   Kozák, Tomáš ^b   Mayer, Jiří ^a,f   Doubek, Michael ^a,f  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^f MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Adults; Immune thrombocytopenia; Response rate; Rituximab

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

ADVERSE OUTCOME; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BRONCHOPNEUMONIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES;

EID: 84872179781     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1206-7     Document Type: Article

References (16)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Br J Haematol. 2006;133:364-74.
2. Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hem Oncol Clin North Am. 2009;23:1213-21.
3. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-93.
4. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-86.
5. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-207.
6. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Inter Med. 2007;146:25-33.
7. Zaja F, Baccarani M, Mazza P, Cocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2012;115:2755-62.
8. Zaja F, Battista ML, Pirrota MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930-3.
9. Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85:329-34.
10. Li Z, Mou W, Lu G, Cao J, He X, Pan X, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93:91-8.
11. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999-1004.
12. Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119:1356-62.
13. Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SMJM, Leufkens HGM, van Solinge WW, Egberts TCG. Rituximabinduced thrombocytopenia: a cohort study. Eur J Haematol. 2012;89:256-66.
14. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti- CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-7.
15. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol. 2010;47:170-9.
16. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol. 2007;14:642-6.